About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT00628290

Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis

A controlled, randomized study on the treatment of schizophrenic psychosis with cannabidiol, a phytocannabinoid is performed. This approach is based upon recent findings indicating that the human endo...

Lead sponsor: University of Cologne•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Cologne

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Clinical diagnosis of schizophrenia or schizophreniform psychosis according to DSM-IV.
•BPRS score \>36 and BPRS psychosis cluster \> 12.
•Ability to provide written informed consent.
•Participants are required an adequate contraception.

Exclusion Criteria

•Any severe neurological or somatic disorder.
•Other psychiatric disorders including addictive disorders.
•Positive urine drug screening for any compound except benzodiazepines.
•No pregnancy or breast feeding.

Related studies

RECRUITINGPhase 3

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

NCT06894212 · Schizophrenia

Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine

NCT06003036 · Schizophrenia, Schizoaffective Disorder

RECRUITINGPhase 2

Synbiotic Compound to Reduce Symptoms of Schizophrenia

NCT04226898 · Schizophrenia, Schizoaffective Disorder

RECRUITINGPhase 2

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

NCT05240976 · Schizophrenia

RECRUITINGPhase 2

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

NCT05052853 · Prodromal Schizophrenia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 18, 2008Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment42

Start dateOct 2002

Last updatedMar 18, 2008

Condition

Locations shown

University of Cologne, Dept. of Psychiatry and Psychotherapy

Cologne, North Rhine-Westphalia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 18, 2008Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions